|
|
Abstract #4
Title: A double-blind controlled evaluation of the sebosuppressive
activity of topical erythromycin-zinc complex.
Title Abreviation: Eur J Clin Pharmacology
Date of Pub: 1995
Author: PiĶerard-Franchimont C; Goffin V; Visser JN; Jacoby H;
PiĶerard GE;
Issue/Part/Supplement: 1-2
Volume Issue: 49
Pagination: 57-60
MESH Headings: Acetic Acids; Acne Vulgaris; Administration, Topical;
Adult; Antibiotics, Macrolide; Double-Blind Method; Drug Therapy, Combination;
Erythromycin; Human; Male; Sebum; -PG-;
Journal Title Code: EN4
Publication Type: CLINICAL TRIAL
Date of Entry: 960923N
Entry Month: 9611
Country: GERMANY
Index Priority: 2
Language: Eng
Unique Identifier: 96287397
Unique Identifier: 96287397
ISSN: 0031-6970
Abstract:
In a double-blind randomised study, 14 volunteers applied
4% erythromycin plus 1.2% zinc (Zineryt lotion) and 4% erythromycin lotions, each
on half of the forehead twice daily for 3 months. The sebum output was evaluated at 3-week
intervals using the photometric and the lipid-sensitive film methods. Evaluations of
casual level (CL) and sebum excretion rate (SER) were made with a Sebumeter, and total
area of lipid spots (TAS) was measured on Sebutapes. Compared to baseline values, the
formulation of the erythromycin-zinc complex induced significant reductions in SER
after 6 and 9 weeks, and in CL and TAS at 3, 6, 9 and 12 weeks. The mean reduction in TAS
was over 20% for four successive 1-h samplings on completion of the study. Significant
reductions in CL, SER and TAS were observed for the erythromycin-zinc formulation
compared to the control lotion at 6 and 9 weeks, and also at 3 weeks for SER and TAS, and
at 12 weeks for CL and TAS. This study indicates that sebum output is significantly
reduced by the erythromycin-zinc complex. This reduction is theoretically
beneficial for the acneic patient.
Abstract By: Author
Address: Department of Dermatopathology, University of Liege,
Belgium.
All Rights Reserved
|
